AstraZeneca's Imfinzi improves survival in limited-stage small cell lung cancer study

05 Apr 2024
Clinical ResultPhase 3Immunotherapy
AstraZeneca’s Imfinzi (durvalumab) significantly improved overall survival (OS) and progression-free survival (PFS) in certain patients with limited-stage small-cell lung cancer (SCLC), the company announced Friday.
The Phase III ADRIATIC study enrolled 730 patients with limited-stage SCLC who had not progressed following concurrent chemoradiotherapy (CRT). Participants were randomised to receive Imfinzi, with or without AstraZeneca’s Imjudo (tremelimumab), or placebo.
Top-line results showed that the Imfinzi arm demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of OS and PFS. Meanwhile, the arm testing the efficacy of Imfinzi plus Imjudo remains blinded and will continue to the next planned analysis.
“ADRIATIC is the first global Phase III immunotherapy trial to deliver significant, clinically meaningful improvement in survival in this setting, marking a breakthrough for patients with this devastating disease,” remarked principal investigator Suresh Senan.
AstraZeneca said that the data will be presented at an upcoming medical meeting and shared with global regulatory authorities.
More to come.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.